MedTrace Logo

Levocarnitine for Dry Eye in Sjogren's Syndrome

NCT03953703 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-04

No results posted yet for this study

Summary

This study evaluates the effectiveness of levocarnitine in the treatment of dry eye in adults with Sjogren's syndrome. This will be a crossover study design with all participants receiving both levocarnitine and placebo.

Conditions

  • Sjogren's Syndrome
  • Keratoconjunctivitis Sicca

Interventions

DRUG

Levocarnitine

Levocarnitine 1000 mg twice per day for 6 weeks

DRUG

Placebo

Placebo 1000 mg twice per day for 6 weeks

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Christine Shieh, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2025-09-19
Completion
2025-09-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03953703 on ClinicalTrials.gov